BUSINESSSCMP WORLD
Chinese biotech giant Wuxi AppTec sees first-half earnings surge amid US scrutiny
Wuxi AppTec, Asia’s largest contract pharmaceutical research provider, reported a 33.7% year-on-year increase in first-half net profit to 11.08 billion yuan, driven by strong demand for weight-loss and diabetes drugs and growth in its US business. The results exceeded Bloomberg analysts' consensus estimates.
Mentioned
Related Signal
Adjacent reporting
- Chinese biotech giant Wuxi AppTec sees first-half earnings surge amid US scrutiny
- Wall Street funds back China’s WuXi AppTec as weight-loss drug orders soar
- Wall Street funds back China’s WuXi AppTec as weight-loss drug orders soar
- Which company could become the Chinese Pfizer? Here are analysts’ top picks
- China AI drug-design deals swell as US scrutiny mounts
- Profits in China’s chipmaking sector soar 2,500% in first half amid AI boom